May 11, 2017 8:07am
Never forgetting facts, cash position and “runways”
Fundamentals are being sidestepped and trampled on ...
But, they will be … b a c k as a measurement tool – speculation does NOT promote a sustainable equity’s pricing!
Lower open expected
Pre-open indications: eight (8), 6 BUYS and 2 SELL
Thursday’s financial results: Asterias Biotherapeutics (NYSEMKT: AST), BioLife Solutions (BLFS), Biostage (BSTG), Cesca Therapeutics (KOOL) and Histogenics (HSGX)
Critical information ahead of “our” universe’s open! I provide intelligence and analysis for short and near-term investment.
Readership is a team sport, are you on it, if your not - kiss your portfolio's value good-bye?
Expectation is the word for 2017 – meeting the unknowns with the soon to be exposed concerns will be the subject of investing decisions throughout this year.
Dow futures are DOWN -0.11% and NASDAQ futures are DOWN -0.25%
U.S. stock index futures pointed to a lower open on Thursday after the Nasdaq notched a record close and a five-day winning streak.
European markets were under pressure as investors digested the latest batch of corporate earnings and reacted to strong gains in oil prices.
Most Asian indexes closed higher and oil prices were up following the mixed close stateside as investors monitored potential fallout of FBI Director James Comey's dismissal.
Data docket: Initial jobless claims and PPI are both due a 8:30 a.m. ET.
The cell therapy sector closed POSITIVE on Wednesday, NEGATIVE on Tuesday, Monday, Friday, and last Thursday.
The cell therapy sector’s record after the last 5 days (of 43 covered companies):
· Wednesday closed POSITIVE with 14 decliners, 27 advancers and 2 flats;
· Tuesday closed NEGATIVE with 22 decliners, 18 advancers and 3 flats;
· Monday closed NEGATIVE with 28 decliners, 12 advancers and 3 flats;
· Friday closed NEGATIVE with 24 decliners, 15 advancers and 4 flats;
· Last Thursday closed NEGATIVE with 21 decliners, 16 advancers and 6 flats;
Remembering Wednesday’s closing bell newsletter, “a surge … I kept saying the cell therapy sector was stalled due to being oversold.”
Reiterating Investors are not as complacent as they have seemed as “our” universe’s companies needs to execute and communicate - utilizing those who “spread the message!”
Recent session have shaken traders as selling has been the only available option. What is investable under $5.00, followed by the $3.00 crowd and the woefull, unlucky they're public under $2.00? Say a prayer for those sector losers who are under a dollar as not even a rogue broker can invest without being called on the carpet!!
Promises, promises - we have all heard the story or as I call the "FAKE" or contrived news - a few companies need to face the music and stoip ripping-off investors ...!
After a while, how can they justify their exixtance?
Thursday’s Q1/17 financial quarterly results:
· Cesca therapeutics (KOOL)
· Asterias Biotherapeutics (NYSEMKT: AST))
· BioLife Solutions (BLFS)
· Biostage (BSTG)
· Histogenics (HSGX)
What did I see on Wednesday, the DOW closed down -0.16% (-32.67) and The NASDAQ closed up +0.14% (+8.56) while volatility traded near 10.
The week has met its mid-point after six (6) of the “usual suspects reported Q1 results - in regard to decliners versus gainers – it framed the state of the sector – slipping:
· Wednesday’s decliners ranged from -0.48% <VTGN> to -7.92% <RGNX> in 14 equities;
· Tuesday’s decliners ranged from -0.07% <MDXG> to -27.70% <CUR> in 22 equities;
· Monday’s decliners ranged from -0.65% <CAPR> to -13.56% <CUR> in 28 equities;
Gainers versus decliners– it also frames the state of the sector - bouncing to the upside in increasing numbers:
· Wednesday’s gainers ranged from +0.03% <OPXA> to +36.18% <CUR> in 27 equities;
· Tuesday’s gainers ranged from +0.04% <CLLS> to +6.41% <JUNO> in 18 equities;
· Monday’s gainers ranged from +0.37% <ONVO> to +11.84% <OSIR> in 12 equities;
Referencing the title, “Fundamentals are being sidestepped or trampled” – tread on or stepped on heavily.
Fundamentals represent the basic qualities and reported information needed to analyze the health and stability of business in question.
This can include topics within both the macroeconomic and microeconomic disciplines that are considered standards for determining the financial values attributed to the asset…
The fundamentals include the qualitative and quantitative information that contributes to the financial valuation of a company or security.
Fundamentals are used to develop an estimate as to whether the underlying asset is considered a worthwhile investment.
You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades?
Watch list:
- The iShares Nasdaq Biotechnology (IBB) closed Wednesday down -0.36%, and is NOT indicating in Thursday’s pre-market;
- The SPDR S&P Biotech ETF (XBI) closed Wednesday down -0.23% and is NOT indicating in Thursday pre-market;
- The Health Care Select Sector SPDR ETF (XLV) closed down -0.29% Wednesday and is NOT indicating in Thursday’s pre-open;
- The iShares Russell 2000 (IWM) closed up +0.62% on Wednesday and is indicating a negative -0.37%% in Thursday’s pre-open
Companies in my headlights - with all the reporting that is about to go on and the resulting influences – the bounces are appearing that I had spoken about …
... Applied Genetic Technologies (AGTC) closed FLAT at $5.95. Post Q1/17 reporting indicated an aftermarket downside signal of -$0.15 or -2.52% - SELL;
Intrexon (XON) closed up +$0.12 to $19.56. Post Q1/17 reporting indicated an aftermarket upside signal of +$1.95 or +44.83% - BUY;
... Sangamo Therapeutics (SGMO) closed down -$0.05 to $4.35. Post Q1/17 reporting indicated an aftermarket upside signal of +$1.95 or +44.83% - BUY;
bluebird bio (BLUE) closed up +$1.15 to $90.45. The aftermarket is indicating a negative -$0.55 or -0.61%. Overbought - BUY to SELL;
... Stemline (STML) closed down -$0.10 to $7.86. The aftermarket is indicating a negative -$0.20 or -2.55% - SELL;
Cellectis SA (CLLS) closed up +$0.27 to $24.06. The aftermarket is indicating a negative -$0.21 or -0.97% - BUY to SELL;
... Regenxbio (RGNX) closed down -$1.50. The aftermarket is indicating a negative -$0.18 or -1.01% - Maintaining SELL;
Verastem (VSTM) closed up +$0.39 to $2.44. The aftermarket is indicating a negative -$0.14 or -5.74% - SELL;
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Henry’s comments are for informational purposes only and are not a substitute for personalized advice. Consult your advisor about what is best for you.
